Literature DB >> 12115308

mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool.

Manfred Hofmann1, Ilka Ruschenburg.   

Abstract

BACKGROUND: It has been found that the members of the BAGE, MAGE, and GAGE gene families are expressed almost exclusively in neoplastic tissues. Normal tissues, except testis and placenta, are negative. Therefore, the expression of these genes may serve as a useful diagnostic marker in detecting malignant disease. The involvement of the serous cavities by malignant neoplasms has important therapeutic and prognostic implications. Accordingly, the diagnosis of peritoneal spread of ovarian carcinoma plays an important role for both initial and second-look staging procedures. In some patients, however, a definite diagnosis cannot be established by morphologic or immunocytologic examination alone. Detection of tumor specific gene expression may be a sensitive additional tool in these settings.
METHODS: The authors studied the gene expression observed in 44 ascites specimens. Gene expression was evaluated by reverse transcription-polymerase chain reaction analysis and sequencing.
RESULTS: Of 44 ascites specimens, the expression of BAGE, MAGE-1, MAGE-3, and GAGE-1/2 was recognized in 17 specimens (63%), 2 specimens (7%), 8 specimens (30%), and 8 specimens (30%) with histologically proven ovarian carcinoma, respectively. Expression of the MAGE and GAGE genes was not observed in patients with nonneoplastic disease, whereas BAGE expression was seen in one patient with cirrhosis.
CONCLUSIONS: These findings show that testing for BAGE, GAGE-1/2, MAGE-1, and MAGE-3 transcriptional activity in ascites specimens results in high sensitivity in diagnosing malignant ascites. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115308     DOI: 10.1002/cncr.10622

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

2.  The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients.

Authors:  Yousri M Hussein; Amal F Gharib; Rasha L Etewa; Amal S El-Shal; Mohamed Esmat Abdel-Ghany; Wael H Elsawy
Journal:  Mol Cell Biochem       Date:  2011-01-25       Impact factor: 3.396

3.  Immunity and immune suppression in human ovarian cancer.

Authors:  Claudia C Preston; Ellen L Goode; Lynn C Hartmann; Kimberly R Kalli; Keith L Knutson
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

Review 4.  The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy.

Authors:  Jianhang Zhao; Zhaoxu Xu; Yan Liu; Xiaobin Wang; Xinli Liu; Yanan Gao; Ying Jin
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

5.  Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.

Authors:  Shiqian Zhang; Xiaoliang Zhou; Hao Yu; Yunhai Yu
Journal:  BMC Cancer       Date:  2010-04-27       Impact factor: 4.430

6.  Functional Module Analysis for Gene Coexpression Networks with Network Integration.

Authors:  Shuqin Zhang; Hongyu Zhao; Michael K Ng
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2015 Sep-Oct       Impact factor: 3.710

7.  Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.

Authors:  Qi Wang; Xuefei Li; Shengxiang Ren; Ningning Cheng; Mingchuan Zhao; Yishi Zhang; Jiayu Li; Weijing Cai; Chao Zhao; Wa Cao; Caicun Zhou
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

8.  Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Authors:  Ghazala Khan; Suzanne E Brooks; Ken I Mills; Barbara-Ann Guinn
Journal:  Biomark Cancer       Date:  2015-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.